Mcl-1 became one of the most investigated members of the Bcl-2 family but the poor availability of specific Bcl-2 family inhibitors specifically targeting this protein hindered improved treatment protocols especially of Mcl-1 overexpressing and chemoresistant cancer types.17, 18. This evidence concerns the gene BCL2 and cancer.